Aligos Therapeutics, Inc. (ALGS)Healthcare | Biotechnology | South San Francisco, United States | NasdaqCM
6.68 USD
-0.98
(-12.794%) ⇩
(April 17, 2026, 4 p.m.
EDT)
After hours: 6.71 +0.03 (0.439%) ⇧ (April 17, 2026, 7:48 p.m. EDT) Short-term: ★☆☆☆☆ | Long-term: ★★★☆☆ | Dividends: ☆☆☆☆☆ |
Hot Take | April 19, 2026, 12:08 a.m. EDT
Aligos Therapeutics presents a high-risk bullish short-term contrarian play due to a massive 22% surge on a China licensing deal, yet technical volatility and severe earnings cliffs make it too unreliable for confident momentum trading, while offering a neutral long-term hold powered solely by high analyst target multiples despite negative current fundamentals and zero dividend history. |
| Model | MAE |
|---|---|
| MSTL ✓ | 0.159156 |
| AutoETS | 0.159832 |
| AutoARIMA | 0.159834 |
| AutoTheta | 0.211170 |
Forecast horizon: 45 days | Selected: MSTL
| Forecast Reliability | |
|---|---|
| Score | 80% |
| H-stat | 0.62 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.256 |
| Excess Kurtosis | -0.27 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 9.805 |
| Revenue per Share | 0.221 |
| Market Cap | 41,334,548 |
| Forward P/E | -1.38 |
| Beta | 2.62 |
| Website | https://www.aligos.com |
| Attribute | Value |
|---|---|
| 52 Week Change | 0.44588745 |
| Address1 | One Corporate Drive |
| Address2 | 2nd Floor |
| All Time High | 937.75 |
| All Time Low | 3.76 |
| Ask | 6.91 |
| Ask Size | 1 |
| Audit Risk | 6 |
| Average Analyst Rating | 1.2 - Strong Buy |
| Average Daily Volume10 Day | 724,180 |
| Average Daily Volume3 Month | 159,459 |
| Average Volume | 159,459 |
| Average Volume10Days | 724,180 |
| Beta | 2.621 |
| Bid | 6.64 |
| Bid Size | 1 |
| Board Risk | 7 |
| Book Value | 8.667 |
| City | South San Francisco |
| Compensation As Of Epoch Date | 1,735,603,200 |
| Compensation Risk | 9 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 6.68 |
| Current Ratio | 3.903 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,774,915,200 |
| Day High | 7.4 |
| Day Low | 6.5201 |
| Debt To Equity | 9.805 |
| Display Name | Aligos Therapeutics |
| Earnings Timestamp | 1,772,717,400 |
| Earnings Timestamp End | 1,777,984,200 |
| Earnings Timestamp Start | 1,777,984,200 |
| Ebitda | -87,055,000 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | 0.359 |
| Enterprise To Revenue | -14.3 |
| Enterprise Value | -31,259,450 |
| Eps Current Year | -6.2778 |
| Eps Forward | -4.85112 |
| Eps Trailing Twelve Months | -2.45 |
| Esg Populated | 0 |
| Exchange | NCM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 7.2533 |
| Fifty Day Average Change | -0.57330036 |
| Fifty Day Average Change Percent | -0.07903993 |
| Fifty Two Week Change Percent | 44.588745 |
| Fifty Two Week High | 13.689 |
| Fifty Two Week High Change | -7.0090003 |
| Fifty Two Week High Change Percent | -0.51201695 |
| Fifty Two Week Low | 4.2 |
| Fifty Two Week Low Change | 2.48 |
| Fifty Two Week Low Change Percent | 0.5904762 |
| Fifty Two Week Range | 4.2 - 13.689 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,602,855,000,000 |
| Float Shares | 3,640,844 |
| Forward Eps | -4.85112 |
| Forward P E | -1.3770015 |
| Free Cashflow | -50,040,624 |
| Full Exchange Name | NasdaqCM |
| Full Time Employees | 82 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,775,001,600 |
| Gross Margins | 0.0 |
| Gross Profits | -67,267,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.103 |
| Held Percent Institutions | 0.55564 |
| Implied Shares Outstanding | 6,187,807 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Ipo Expected Date | 2,020-10-16 |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Last Split Date | 1,724,025,600 |
| Last Split Factor | 1:25 |
| Long Business Summary | Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in liver and viral diseases. Its drug candidate, ALG-055009, a small molecule THR-ß agonist that is in the Phase 2a clinical trial for the treatment of metabolic dysfunction-associated steatohepatitis and obesity. The company also develops pevifoscorvir sodium, a capsid assembly modulator, which is in Phase 2 B clinical trial; and ALG-097558, a small molecule ritonavir-free pan-coronavirus protease inhibitor which has completed a Phase 1 clinical trial for the treatment of coronavirus. The company has entered into license and research collaboration agreement with Emory University; and Katholieke Universiteit Leuven. Aligos Therapeutics, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California. |
| Long Name | Aligos Therapeutics, Inc. |
| Market | us_market |
| Market Cap | 41,334,548 |
| Market State | CLOSED |
| Max Age | 86,400 |
| Message Board Id | finmb_581475891 |
| Most Recent Quarter | 1,767,139,200 |
| Net Income To Common | -24,193,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 41,334,550 |
| Number Of Analyst Opinions | 5 |
| Open | 7.32 |
| Operating Cashflow | -82,503,000 |
| Operating Margins | -129.07692 |
| Overall Risk | 8 |
| Payout Ratio | 0.0 |
| Phone | 800 466 6059 |
| Post Market Change | 0.029300213 |
| Post Market Change Percent | 0.43862596 |
| Post Market Price | 6.7093 |
| Post Market Time | 1,776,469,708 |
| Previous Close | 7.66 |
| Price Eps Current Year | -1.064067 |
| Price Hint | 2 |
| Price To Book | 0.77073956 |
| Price To Sales Trailing12 Months | 18.90876 |
| Profit Margins | 0.0 |
| Quick Ratio | 3.666 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | strong_buy |
| Recommendation Mean | 1.2 |
| Region | US |
| Regular Market Change | -0.98 |
| Regular Market Change Percent | -12.7937 |
| Regular Market Day High | 7.4 |
| Regular Market Day Low | 6.5201 |
| Regular Market Day Range | 6.5201 - 7.4 |
| Regular Market Open | 7.32 |
| Regular Market Previous Close | 7.66 |
| Regular Market Price | 6.68 |
| Regular Market Time | 1,776,456,001 |
| Regular Market Volume | 815,287 |
| Return On Assets | -0.69333 |
| Return On Equity | -1.96915 |
| Revenue Growth | -0.731 |
| Revenue Per Share | 0.221 |
| Sand P52 Week Change | 0.38150132 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 8 |
| Shares Outstanding | 5,387,807 |
| Shares Percent Shares Out | 0.0495 |
| Shares Short | 306,176 |
| Shares Short Previous Month Date | 1,772,150,400 |
| Shares Short Prior Month | 289,814 |
| Short Name | Aligos Therapeutics, Inc. |
| Short Percent Of Float | 0.0581 |
| Short Ratio | 7.02 |
| Source Interval | 15 |
| State | CA |
| Symbol | ALGS |
| Target High Price | 175.0 |
| Target Low Price | 20.0 |
| Target Mean Price | 65.8 |
| Target Median Price | 48.0 |
| Total Cash | 77,844,000 |
| Total Cash Per Share | 12.58 |
| Total Debt | 5,250,000 |
| Total Revenue | 2,186,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -2.45 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 8.69375 |
| Two Hundred Day Average Change | -2.0137506 |
| Two Hundred Day Average Change Percent | -0.23163198 |
| Type Disp | Equity |
| Volume | 815,287 |
| Website | https://www.aligos.com |
| Zip | 94,080 |